23 February, 2022
Crescom selected for AI convergence review and reading system construction project by HIRA

(Picture: CEO Jaejoon Lee(left) explaining the company's AI medical image reading solution to the Vice Minister of Science and ICT)

(Date: July 30, 2021)

 Crescom Co., Ltd. (CEO Jaejoon Lee), specializing in artificial intelligence analysis solutions for musculoskeletal medical data, announced that it was finally selected for the ‘AI convergence medical image reading system construction project’ hosted by the Health Insurance Review and Assessment Service and the Information and Communication Industry Promotion Agency. For this project, Crescom, Idot, and JLK companies were finally selected.

 Crescom formed a consortium with Seoul National University Boramae Hospital, Seoul National University Bundang Hospital, and Korea University Anam Hospital to develop artificial intelligence (AI) solutions for diagnosis and examination of knee arthritis for three years. The developed solution is used to support the diagnosis of knee degenerative arthritis in the medical field and the review of the HIRA.

 As a company selected for this project, AI solutions were demonstrated at the opening ceremony of the ‘Artificial Intelligence Convergence AI+X Project Medical Data Utilization Demonstration Lab’ held at the Health Insurance Review and Assessment Service Headquarters in Wonju, Gangwon-do, on the 28th. In this event, Prime Minister Bu-gyeom Kim, National Assembly member Kwang-jae Lee, and Ki-heon Song, as well as major officials from the Ministry of Science and ICT, the Ministry of Health and Welfare of South Korea, the Ministry of Food and Drug Safety(MFDS), the Health Insurance Review and Assessment Service(HIRA), and the National IT Industry Promotion Agency (NIPA) attended the event to experience the solution demonstrations of participating companies. and communicated with entrepreneurs.

 Crescom's patented technology leads 'MediAI-BA' which is integrated the strengths of existing bone age reading methods GP and TW3 growth plate inspection artificial intelligence solution and 'MediAI-FX' which is the artificial intelligence fracture detection solution. These solutions can help with timely, quick and accurate reading in the medical field.

 ‘MediAI-BA’ has been confirmed to be useful in the medical field in clinical trials for approval by the Ministry of Food and Drug Safety, and is currently helping to analyze the age of growth plates in children in more than 100 hospitals in Korea. ‘MediAI-FX’ can detect scaphoid fractures that cause serious sequelae when left unattended although the fractures are usually difficult to find out. The wrist fracture detection AI solution is currently in the final stage of clinical trials.

 Crescom CEO Jaejoon Lee said, “Based on the support of the Ministry of Science and ICT and the Health Insurance Review and Assessment Service, we want to be helpful in the medical field and medical examination, and we will do our best to advance into the global market so that it can be widely used not only in Korea but also in overseas markets.”